Abstract
The development of bone metastasis from renal cell carcinoma (RCC) signals a transition to a terminal state for the patient with previously isolated disease. These patients may suffer the morbidity of severe, persistent pain, pathologic fractures, and spinal compression from vertebral metastasis before they succumb to their cancer. Although recent advancements have been made in the understanding of breast and prostate bone metastasis, there has been less knowledge in the area of metastatic RCC to the skeleton. This particular cancer in bone remains relatively resistant to standard forms of treatment such as radiation and chemotherapy. A better understanding of the biology of RCC bone metastasis is critically needed in order to improve treatment. Bone-derived cell lines and an experimental animal model have been developed in order to explore the relevant mechanisms of how RCC cells survive within and destroy the bone. This review will focus on the growth factor signaling pathways most important for the RCC-stimulated osteoclast-mediated bone destruction, namely the epidermal growth factor receptor (EGF-R) and transforming growth factor-β receptor (TGF-βR) pathways. By inhibiting these receptors, growth of RCC within the bone is decreased which, directly or indirectly, decreases bone destruction.
Similar content being viewed by others
References
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., et al. (2004). Cancer statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 8–9
Weber, K. L., Lewis, V. O., Randall, R. L., Lee, A. K., & Springfield, D. (2004). An approach to the management of the patient with metastatic bone disease. Instructional Course Lectures, 53, 663–76.
Berenson, J. R. (2005). Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist, 10, 52–2.
Kedar, I., Mermershtain, W., & Ivgi, H. (2004). Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. International Journal of Cancer, 110, 260–65.
Porta, C., Zimatore, M., Imarisio, I., Natalizi, A., Sartore-Bianchi, A., Danova, M., et al. (2004). Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: Final results of a single-institution Phase II study. Cancer, 100, 2132–138.
Russo, P. (2000). Renal cell carcinoma: Presentation, staging, and surgical treatment. Seminars in Oncology, 27, 160–76.
Durr, H. R., Maier, M., Pfahler, M., Baur, A., & Refior, H. J. (1999). Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clinical Orthopaedics and Related Research, 283–90.
O’Connor, M., & Weber, K. (2003). Indications and operative treatment for long bone metastasis with a focus on the femur. Clinical Orthopaedics and Related Research, 415S, 276–78.
Weber, K. L. (2004). What’s new in musculoskeletal oncology. Journal of Bone and Joint Surgery. American Volume, 86-A, 1104–109.
Guise, T. A., Yin, J. J., Thomas, R. J., Dallas, M., Cui, Y., & Gillespie, M. T. (2002). Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone, 30, 670–76.
Kakonen, S. M., Selander, K. S., Chirgwin, J. M., Yin, J. J., Burns, S., Rankin, W. A., et al. (2002). Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Journal of Biological Chemistry 277, 24571–4578.
Chirgwin, J. M., Mohammad, K. S., & Guise, T. A. (2004). Tumor’bone cellular interactions in skeletal metastases. Journal of Musculoskeletal Neuronal Interactions, 4, 308–18.
Guise, T. A., Yin, J. J., & Mohammad, K. S. (2003). Role of endothelin-1 in osteoblastic bone metastases. Cancer, 97, 779–84.
Yin, J. J., Mohammad, K. S., Kakonen, S. M., Harris, S., Wu-Wong, J. R., Wessale, J. L., et al. (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America, 100, 10954–0959.
Weber, K. L., Pathak, S., Multani, A. S., & Price, J. E. (2002). Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model. Journal of Urology, 168, 774–79.
Mydlo, J. H., Michaeli, J., Cordon-Cardo, C., Goldenberg, A. S., Heston, W. D., & Fair, W. R. (1989). Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Research, 49, 3407–411.
Sargent, E. R., Gomella, L. G., Belldegrun, A., Linehan, W. M., & Kasid, A. (1989). Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. Journal of Urology, 142, 1364–368.
Stumm, G., Eberwein, S., Rostock-Wolf, S., Stein, H., Pomer, S., Schlegel, J., et al. (1996). Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. International Journal of Cancer, 69, 17–2.
Moch, H., Sauter, G., Buchholz, N., Gasser, T. C., Bubendorf, L., Waldman, F. M., et al. (1997). Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Human Pathology, 28, 1255–259.
Atlas, I., Mendelsohn, J., Baselga, J., Fair, W. R., Masui, H., & Kumar, R. (1992). Growth regulation of human renal carcinoma cells: Role of transforming growth factor alpha. Cancer Research, 52, 3335–339.
Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. (2000). Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Research, 60, 2926–935.
Mendelsohn, J. (1997). Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clinical Cancer Research, 3, 2703–707.
Prewett, M., Rothman, M., Waksal, H., Feldman, M., Bander, N. H., & Hicklin, D. J. (1998). Mouse’human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clinical Cancer Research, 4, 2957–966.
Weber, K. (2003). Epidermal growth factor receptor signaling in renal cell carcinoma bone metastasis. In Molecular biology in orthopaedics (pp. 163–71), AAOS/NIH Textbook.
Weber, K. L., Doucet, M., & Price, J. E. (2003). Renal cell carcinoma bone metastasis: Epidermal growth factor receptor targeting. Clinical Orthopaedics and Related Research, S86’S94.
Weber, K. L., Doucet, M., Price, J. E., Baker, C., Kim, S. J., & Fidler, I. J. (2003). Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Research, 63, 2940–947.
Baker, C. H., Solorzano, C. C., & Fidler, I. J. (2002). Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Research, 62, 1996–003.
Shiurba, R. A., Eng, L. F., Vogel, H., Lee, Y. L., Horoupian, D. S., & Urich, H. (1988). Epidermal growth factor receptor in meningiomas is expressed predominantly on endothelial cells. Cancer, 62, 2139–144.
Langley, R. R., Ramirez, K. M., Tsan, R. Z., Van Arsdall, M., Nilsson, M. B., & Fidler, I. J. (2003). Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Research, 63, 2971–976.
Traxler, P. B. E., Furet, P., et al. (1999). Preclinical profile of PKI166: A novel and potent EGF-R tyrosine kinase inhibitor for clinical development. Clinical Cancer Research, 5, 3750.
Yokoi, K., Thaker, P. H., Yazici, S., Rebhun, R. R., Nam, D. H., He, J., et al. (2005). Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Research, 65, 3716–725.
Younes, M. N., Yigitbasi, O. G., Park, Y. W., Kim, S. J., Jasser, S. A., Hawthorne, V. S., et al. (2005). Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Research, 65, 4716–727.
Baker, C. H., Kedar, D., McCarty, M. F., Tsan, R., Weber, K. L., Bucana, C. D., et al. (2002). Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. American Journal of Pathology, 161, 929–38.
Senaratne, S. G., Mansi, J. L., & Colston, K. W. (2002). The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. British Journal of Cancer, 86, 1479–486.
Dumont, N., & Arteaga, C. L. (2003). Targeting the TGF beta signaling network in human neoplasia. Cancer Cell, 3, 531–36.
Derynck, R., Akhurst, R. J., & Balmain, A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nature Genetics, 29, 117–29.
Massague, J., Blain, S. W., & Lo, R. S. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell, 103, 295–09.
Siegel, P. M., & Massague, J. (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nature Reviews. Cancer, 3, 807–21.
Wakefield, L. M., & Roberts, A. B. (2002). TGF-beta signaling: Positive and negative effects on tumorigenesis. Current Opinion in Genetics & Development, 12, 22–9.
Mundy, G. R. (2002). Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Reviews. Cancer, 2, 584–93.
Roodman, G. D. (1993). Role of cytokines in the regulation of bone resorption. Calcified Tissue International, 53(Suppl 1):S94’S98.
Kominsky, S., Doucet, M., Brady, K., & Weber, K. L. (2007). TGF-β influences the development of renal cell carcinoma bone metastasis. Journal of Bone and Mineral Research, 22, 37–4.
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004). Development of TGF-beta signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery, 3, 1011–022.
Paule, B., Clerc, D., Rudant, C., Coulombel, C., Bonhomme-Faivre, L., Quillard, J., et al. (1998). Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Human Pathology, 29, 421–24.
Kwan Tat, S., Padrines, M., Théoleyre, S., Heymann, D., Fortun, Y. (2004). I:-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews, 15, 49–0.
Negrier, S., Perol, D., Menetrier-Caux, C., Escudier, B., Pallardy, M., Ravaud, A., et al. (2004). Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6-from the Groupe Francais d’Immunotherapie. Journal of Clinical Oncology, 22, 2371–378.
Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., et al. (1989). Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Letters, 250, 607–10.
O’Brien, C. A., Gubrij, I., Lin, S. C., Saylors, R. L., & Manolagas, S. C. (1999). STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. Journal of Biological Chemistry, 274, 19301–9308.
Park, J. I., Lee, M. G., Cho, K., Park, B. J., Chae, K. S., Byun, D. S., et al. (2003). Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene, 22, 4314–332.
Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer, 2, 161–74.
Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology, 17, 463–16.
Kusano, K., Miyaura, C., Inada, M., Tamura, T., Ito, A., Nagase, H., et al. (1998). Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology, 139, 1338–345.
Selvamurugan, N., Kwok, S., Alliston, T., Reiss, M., & Partridge, N. C. (2004). Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. Journal of Biological Chemistry, 279, 19327–9334.
Ueda, M., Fujii, H., Yoshizawa, K., Terai, Y., Kumagai, K., Ueki, K., et al. (1998). Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells. Invasion Metastasis, 18, 176–83.
Fuller, K., & Chambers, T. J. (1995). Localisation of mRNA for collagenase in osteocytic, bone surface and chondrocytic cells but not osteoclasts. Journal of Cell Science, 108(Pt 6), 2221–230.
Holliday, L. S., Welgus, H. G., Fliszar, C. J., Veith, G. M., Jeffrey, J. J., & Gluck, S. L. (1997). Initiation of osteoclast bone resorption by interstitial collagenase. Journal of Biological Chemistry, 272, 22053–2058.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weber, K., Doucet, M. & Kominsky, S. Renal cell carcinoma bone metastasis—elucidating the molecular targets. Cancer Metastasis Rev 26, 691–704 (2007). https://doi.org/10.1007/s10555-007-9090-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-007-9090-y